"The latter question is not one the drug companies will spend money to answer," Ms Menzies noted.
"If there is a lesson from the events of the last weeks and years," Dr Buse told the panel, "perhaps it is that upon filing a New Drug Application, pharmaceutical manufacturers should make every effort to develop an adequately-powered independently-executed study that examines clinically meaningful endpoints such as heart attack or loss of vision."
"In parallel with regulatory approval," he stated, "such a study should be reviewed with attention to design, oversight, funding plan and timeline, recognizing that such studies are very expensive and will take many years to complete."
Dr Psaty also told the Committee that: "Direct-to-consumer advertising increases demand for drugs, some of which, like Avandia, may have been incompletely evaluated."
At the hearing, FDA Commissioner Andrew von Eschenbach announced that the FDA has asked the drug makers to add a black box warning about the risk of congestive heart failure to the labels of Avandia and Actos.
Persons seeking legal advice regarding Avandia can contact Baum Hedlund Law Firm at: (800) 827-0087; http://www.baumhedlundlaw.com/
http://www.avandia-heart-lawyers.com/
Evelyn Pringle
evelyn-pringle@sbcglobal.net
(Written as part of a series on Avandia sponsored by Baum Hedlund's Pharmaceutical Litigation Department)
(Evelyn Pringle is a regular columnist for OpEd News and investigative journalist focused on exposing corruption in government and corporate America)
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
